Syringe and Needle - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The syringe and needle market size is expected to grow from USD 26.50 billion in 2025 to USD 28.49 billion in 2026 and is forecast to reach USD 40.95 billion by 2031 at 7.53% CAGR over 2026-2031. This report is Segmented by Product Category (Syringes [Disposable and Reusable] and Needles [Hypodermic and More]), Material (Plastic, Glass, and More), Application (Insulin Administration, Vaccination, and More), End User (Hospitals and Clinics, Ambulatory Surgery Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global Syringe and Needle Market Trends and Insights

Surging GLP-1 & Other Biologic Injectables Pipeline

The shift toward high-viscosity biologics pushes manufacturers to develop syringes that can withstand pressures created by formulations up to 30 mL. BD’s Neopak XtraFlow glass platform integrates thinner-wall cannulas to maintain glide force within patient-acceptable ranges . Pharmaceutical firms favor prefilled formats because they improve dose accuracy; as a result, the global prefilled syringe segment is on track to double by 2027. Autoinjector demand also rises, with the category forecast to hit USD 19.67 billion by 2028 on the back of chronic disease self-care. The combination of biologic R&D pipelines and monthly dosing regimens enlarges the syringe and needle market far beyond historical insulin-focused volumes.

Mass Adult Booster Immunization Programs

Influenza and COVID-19 booster uptake among U.S. adults reached 34.7% and 17.9% respectively in November 2024, creating recurring annual demand spikes for injection devices . Advisory bodies now recommend routine RSV vaccination for adults ≥75 years, locking in baseline global syringe volumes each respiratory season. High-throughput immunization settings favor safety-engineered, prefilled devices that cut preparation time and reduce worker exposure to sharps.

Growing Cases of Needle-Stick Injuries & Risk of Cross-Contamination

OSHA estimates 600,000 needle-stick injuries occur annually in U.S. hospitals despite mandated safety devices. Outbreaks linked to contaminated syringes underscore patient-to-patient transmission risks, elevating costs tied to post-exposure prophylaxis and litigation .

Other drivers and restraints analyzed in the detailed report include:

• High and Rising Burden of Chronic & Infectious Diseases
• Increased Adoption of Injectable Drugs for Out-Patient Care
• Availability & Rapid Progress of Needle-Free Delivery Technologies

Segment Analysis

Syringes captured 74.86% of the syringe and needle market share in 2025, underlining their indispensability across therapeutic areas. Disposable variants predominate because infection-control protocols favor single-use devices. Reusable syringes persist only where sterilization controls are economically justified. Needles, though smaller in revenue today, post an 8.12% CAGR to 2031 as hospitals adopt passive safety mechanisms that shield the tip immediately after use.

Technological variety within the needle subsegment fuels this performance. Hypodermic models remain workhorses for vaccination and drug administration, whereas intravenous needles accelerate on the back of outpatient infusion growth. Ophthalmic and dental specialists demand ultra-fine gauges for precision procedures, creating niche premium-price categories. Manufacturers overlay RFID tags on high-value syringes, enabling real-time inventory visibility for hospital pharmacies and reducing wastage from expired stock.

Plastic retained 52.05% share of the syringe and needle market in 2025 as polypropylene, polyethylene and COC blends provided low-cost moldability and gamma-sterilization compatibility. Glass continues to rule premium prefilled formats because it minimizes drug-container interaction for biologics with high surface sensitivity. Yet stainless-steel barrels re-enter the mainstream, growing at 8.01% CAGR through 2031, buoyed by the need for rugged delivery systems that handle viscous GLP-1 formulations without barrel flex. Raw-material inflation and resin supply shocks illustrate why device firms diversify material portfolios and on-shore strategic inventory.

Glass investments reinforce confidence: Gerresheimer allocated EUR 100 million to scale syringe capacity at its Skopje plant, while Nipro upgraded German lines for dual-flange (D2F) formats that pair seamlessly with autoinjectors. Such projects broaden geographical redundancy, a priority after pandemic-era freight bottlenecks.

Complete Report Scope:

• By Product Category
  • Syringes
    • Disposable
    • Reusable
  • Needles
    • Hypodermic
    • Intravenous
    • Intramuscular
    • Others
• By Material
  • Plastic
  • Glass
  • Stainless Steel
• By Application
  • Insulin Administration
  • Vaccination
  • Osteoarthritis
  • Botox
  • Blood Collection
  • Ophthalmic Procedures
  • Dental
  • Other Applications
• By End User
  • Hospitals and Clinics
  • Ambulatory Surgery Centers
  • Diagnostic Laboratories
  • Home Healthcare Settings
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the syringe and needle market with 39.18% share in 2025. Domestic producers capitalized on FDA safety communications that curtailed certain Chinese imports, elevating demand for compliant, traceable alternatives. BD’s USD 10 million expansion added 40% safety-engineered syringe capacity and 50% conventional syringe output across Connecticut and Nebraska, fortifying regional supply resilience.

Europe remained a stronghold owing to stringent quality norms and aging populations that boost chronic-care injections. Investments such as Gerresheimer’s glass line scale-up and Nipro’s D2F upgrades underscore the region’s role in premium biologic delivery solutions. Sustainability rules, especially extended-producer responsibility mandates, spur innovation in recyclable components and low-waste packaging.

Asia-Pacific is the fastest-growing zone at 8.43% CAGR. India aims for a USD 50 billion medical-device economy by 2025 and has aligned domestic regulations with ISO standards to attract foreign OEM partnerships. Chinese manufacturers pivot from volume to value, investing in class-III device certification and building joint ventures in Southeast Asia to diversify market exposure. Large patient pools needing chronic therapy, coupled with public-hospital modernization, sustain a rising baseline for syringe and needle market demand across the region.

List of Companies Covered in this Report:

• Beckton Dickinson
• Terumo
• B. Braun
• Nipro
• Cardinal Health
• Gerresheimer
• Hindustan Syringes & Medical Devices
• SCHOTT
• Smiths Group
• Henry Schein
• DeRoyal Industries
• Connecticut Hypodermics
• Medtronic
• Retractable Technologies
• West Pharmaceutical Services
• Hamilton Company
• Vetter Pharma International
• Ultimed
• Jiangsu Delfu medical
• Zhejiang Jianfeng Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support